This Article Full Text Full Text (PDF) All Versions of this Article: 36/10/2238    most recent 01.STR.0000181779.83472.35v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, Y.-M. Articles by Lee, J.-K. Search for Related Content PubMed PubMed Citation Articles by Yu, Y.-M. Articles by Lee, J.-K. Related Collections Animal models of human disease Acute Cerebral Infarction Neuroprotectors

(Stroke. 2005;36:2238.)
© 2005 American Heart Association, Inc.

Original Contributions

Inhibition of the Cerebral Ischemic Injury by Ethyl Pyruvate With a Wide Therapeutic Window

Young-Mi Yu; Jung-Bin Kim; Kang-Woo Lee, PhD; Seong Yun Kim, MD, PhD; Pyung-Lim Han, PhD Ja-Kyeong Lee, PhD

From the Department of Anatomy (Y.-M.Y., J.-B.K., J.-K.L.), Inha University School of Medicine, Inchon, Korea; Department of Neuroscience and EIN (K.-W.L., P.-L.H.), Ewha Womans University School of Medicine, Seoul, Korea; and the Department of Pharmacology (S.Y.K.), The Catholic University School of Medicine, Seoul, Korea.

Correspondence to Ja-Kyeong Lee, PhD, Department of Anatomy, Inha University School of Medicine, 7-241 Shinheung-dong, Jung-Gu, Inchon, 400-712, Republic of Korea. E-mail jklee{at}inha.ac.kr

Background and Purpose— Ethyl pyruvate (EP) is a pyruvate derivative that has been reported recently to prevent lethality in mice with established lethal sepsis and systemic inflammation. In this study, we examined the neuroprotective effect of EP in a rat cerebral ischemia model of middle cerebral artery occlusion (MCAO).

Methods— Male Sprague-Dawley rats were subjected to 1 hour of MCAO, and EP was administered at various time points before or after MCAO. The changes in the brain infarction, neurological deficits, microglia activation, and proinflammatory cytokine expression were evaluated. BV2 microglial cells were also used to access the anti-inflammatory effect of EP.

Results— The administration of EP intraperitoneally at 30 minutes before or at 4 or 12 hours after MCAO reduced the infarct volume to 10.3±3.4% (n=6; P<0.05), 21.5±2.7% (n=6; P<0.05), and 44.3±4.0% (n=6; P<0.05), respectively, of that of the control group. The significant reduction in infarct volume was accompanied by the suppression of the clinical manifestations associated with cerebral ischemia, including motor impairment and neurological deficits, microglial activation, and proinflammatory cytokine expression. The neuroprotective effect of EP was yet evident when it was administered as late as 24 hours after MCAO/reperfusion (76.5±4.70%; n=6; P<0.05). EP suppressed lipopolysaccharide induced activation of BV2 cells, as was evidenced by a reduction in NO release and the accompanying induction of proinflammatory cytokines.

Conclusions— These results suggest that EP affords the strong protection of the delayed cerebral ischemic injury with a wide therapeutic window.

Key Words: middle cerebral artery occlusion • microglia • inflammation • neuroprotection

This article has been cited by other articles:

				J. Lee, W. Kwon, Y. Jo, G. Suh, and Y. Youn Protective effects of ethyl pyruvate treatment on paraquat-intoxicated rats Human and Experimental Toxicology, January 1, 2008; 27(1): 49 - 54. [Abstract] [PDF]